Cell therapy of severe ischemia in people with diabetic foot ulcers-do we have enough evidence?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F23%3A00084327" target="_blank" >RIV/00023001:_____/23:00084327 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/23:10469516

Výsledek na webu

<a href="https://link.springer.com/article/10.1007/s40291-023-00667-w" target="_blank" >https://link.springer.com/article/10.1007/s40291-023-00667-w</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s40291-023-00667-w" target="_blank" >10.1007/s40291-023-00667-w</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Cell therapy of severe ischemia in people with diabetic foot ulcers-do we have enough evidence?

Popis výsledku v původním jazyce

This current opinion article critically evaluates the efficacy of autologous cell therapy (ACT) for chronic limb-threatening ischemia (CLTI), especially in people with diabetes who are not candidates for standard revascularization. This treatment approach has been used in &apos;no-option&apos; CLTI in the last two decades and more than 1700 patients have received ACT worldwide. Here we analyze the level of published evidence of ACT as well as our experience with this treatment method. Many studies have shown that ACT is safe and an effective method for patients with the most severe lower limb ischemia. However, some trials did not show any benefit of ACT, and there is some heterogeneity in the types of injected cells, route of administration and assessed endpoints. Nevertheless, we believe that ACT plays an important role in a comprehensive treatment of patients with diabetic foot and severe ischemia.

Název v anglickém jazyce

Cell therapy of severe ischemia in people with diabetic foot ulcers-do we have enough evidence?

Popis výsledku anglicky

This current opinion article critically evaluates the efficacy of autologous cell therapy (ACT) for chronic limb-threatening ischemia (CLTI), especially in people with diabetes who are not candidates for standard revascularization. This treatment approach has been used in &apos;no-option&apos; CLTI in the last two decades and more than 1700 patients have received ACT worldwide. Here we analyze the level of published evidence of ACT as well as our experience with this treatment method. Many studies have shown that ACT is safe and an effective method for patients with the most severe lower limb ischemia. However, some trials did not show any benefit of ACT, and there is some heterogeneity in the types of injected cells, route of administration and assessed endpoints. Nevertheless, we believe that ACT plays an important role in a comprehensive treatment of patients with diabetic foot and severe ischemia.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

<a href="/cs/project/LX22NPO5104" target="_blank" >LX22NPO5104: Národní institut pro výzkum metabolických a kardiovaskulárních onemocnění</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Molecular diagnosis and therapy

ISSN

1177-1062

e-ISSN

1179-2000

Svazek periodika

27

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

NZ - Nový Zéland

Počet stran výsledku

11

Strana od-do

673-683

Kód UT WoS článku

001069952500001

EID výsledku v databázi Scopus

2-s2.0-85171735704